Prognostic value of a modified systemic inflammation score in breast cancer patients who underwent neoadjuvant chemotherapy.

ABSTRACT:

Background and purpose

The modified systemic inflammation score (mSIS) system, which is constructed based on the neutrophil to lymphocyte ratio (NLR) and albumin (Alb), has not been applied to evaluate the prognosis of malignant breast cancer patients who underwent neoadjuvant chemotherapy (NAC). The present study aimed to explore the relationship between the mSIS and overall survival (OS), disease-free survival (DFS) and pathological complete response (pCR).

Methods

A total of 305 malignant breast tumor patients who underwent NAC were incorporated into this retrospective analysis. We determined OS and DFS using K-M survival curves and the log-rank test. The relationship between the mSIS and OS and DFS was evaluated by a Cox regression model. A nomogram was constructed based

SUBMITTER: Jiang C 

PROVIDER: S-EPMC9717545 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature